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An encouraging start
We have just passed the halfway mark for 
the VISION 2020 global initiative, which 
was launched in 1999 with the goal to 
eliminate avoidable blindness by the year 
2020. This is a good time to take stock of 
what we have achieved and what still 
needs to be done.
The success of VISION 2020 has to be 
judged against its impact on reducing 
levels of avoidable blindness in the world. 
Although still to be finally approved by 
WHO, some preliminary data on the global 
prevalence of blindness and visual 
impairment was presented in a meeting 
between WHO and IAPB members in 
October 2010. It suggests a decline of 
approximately 10% in the overall number 
of blind and visually impaired. Compared 
to the 314 million people with visual 
impairment (≤6/18) from WHO data 
produced in 2004, the new figures 
suggest a total of 285 million. Overall, 
this is a decrease of nearly 29 million. 
The number of blind people (≤3/60, 
presenting vision) has fallen from an 
estimated 45 million to 39.8 million. If 
these figures are confirmed, and if we 
take into account that, over the same 
period, there has been an 18% increase 
in the population of those aged 50 years 
and older worldwide, then we have some 
cause for optimism.
We also know that: 
• The prevalence of blindness is decreasing 
in some countries that have adopted 
VISION 2020 strategies. The most 
recent national studies done in 
Pakistan, India, and The Gambia 
have all shown significant declines 
in prevalence rates compared to 
earlier surveys.
• The number of cataract operations 
done in India has increased fivefold over 
the past 25 years, to more than 5 million 
per year, and the lessons learnt are 
having a major positive impact in 
other countries.
• Blindness due to trachoma and 
onchocerciasis has decreased 
significantly and the possibility of the 
elimination of transmission of these 
two diseases by the year 2020 is 
within reach.
• Childhood blindness is decreasing due 
Normally, data is further centralised at 
the provincial level before being passed to 
the central level where it is forwarded to 
the supporting programmes and the drug 
donation programme. There has been an 
effort to get treatment data integrated 
into existing health management infor-
mation systems in countries, but this has 
been a slow process, and there are many 
discussions about which indicators to 
use. As health systems are often weak at 
the periphery (e.g. remote or rural areas), 
community data may be collected by a 
supporting non-governmental organisation 
(NGO) in a parallel way and then 
forwarded to the government for their 
reports. Mectizan® is often donated 
through NGOs, so they are an important 
part of the process. 
People need to be trained at the 
respective levels in order to collect this 
vital information. Once chosen by their 
community, distributors are trained in a 
very practical way, as close as possible to 
their community. Treatment is usually 
written down for each individual, and by 
family, in a locally bought exercise book or 
in specially printed registers. In some 
remote communities, volunteers may be 
illiterate. However, even in these circum-
stances, volunteers can be trained to use 
a simple tally sheet, which is often used 
to summarise data in any case. Training 
at the community level is usually done by 
the health centre staff who are in turn 
trained by staff at the district level, who 
have received their training at a provincial 
level. This form of ‘cascade’ training is a 
very effective process, but care must be 
taken to make sure the essential 
messages are relayed correctly at the 
relevant levels. Close supervision is required 
as incorrect data leads to incorrect tablet 
data or information for planning. 
During the distribution process, the 
distributors are often helped by other 
volunteers to enter data into the exercise 
book or register. Having one page per 
household makes it easier to locate 
individuals for follow-up of the annual 
treatment or to find people who were 
absent at the time of treatment.
The treatment summaries are 
prepared at the community level. These 
show numbers treated by gender and 
sometimes by dose (1–4 tablets) and 
also reasons for not taking the tablets 
(too young, pregnant, too ill, absent from 
the village, etc.). The health area nurse 
then collects data from all the commu-
nities and forwards it to the health district 
where it is centralised, sometimes 
computerised, and then forwarded to 
higher levels with their own activity report. 
Once again, NGOs sometimes facilitate 
this process.
How is the information 
analysed and used?
The data collected by the volunteers are 
usually analysed at the community level 
and the following are calculated: total 
number of people treated, number of 
tablets used, and sometimes coverage 
(percentage or proportion of population 
treated). Volunteers may also use the 
family treatment sheets to follow up on 
those who had not received treatment, 
often revisiting their homes. They may 
also try to follow up on people refusing 
treatment. Specially trained community 
volunteers may also participate in this 
analysis and may calculate the coverage. 
Health centre nurses usually discuss the 
results with community volunteers and 
will check the coverage levels. At the 
district level, health centres are compared 
and the results are tabulated and 
coverage calculated before the report is 
forwarded to the provincial or central level.
The information is used in different 
ways at different levels: 
• At the community level, the details of 
treatment are shared and the coverage 
is discussed with the community 
distributors, including the importance of 
high coverage for control or elimination. 
Problems or low coverage are discussed 
to try and resolve challenges. 
Sometimes, coverage is compared 
between communities to see “who is 
doing best.” 
• At the health centre level, coverage is 
calculated: people responsible for high 
coverage are congratulated; 
discussions are held with those with low 
coverage and solutions examined. At 
this time, strategies for the next 
treatment round will be discussed and 
the needs for tablets will be calculated. 
• At the district level, coverage is again 
the main issue as well as planning and 
budgeting for the next treatment round 
(training, retraining, further health 
education, etc.). 
• At the central (national) level, the 
reports are used to calculate the next 
year’s tablet request.
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Community distributors can use the data 
they collect to do a follow-up. BurunDi
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to vitamin A supplementation, measles 
immunisation, and the focus on blinding 
conditions such as retinopathy of 
prematurity.
• Half of the world’s visual impairment is 
due to uncorrected refractive error, and 
significant progress has been made in 
bringing refraction and spectacle 
making to the poorest communities. 
Scaling up and adopting 
new strategies
But much more needs to be done if we 
are to achieve our overall objective. The 
way forward will require us to build upon 
existing success, to ‘scale up’ what we 
are already doing (by going from project 
level to full country-wide programmes), 
and to adopt new strategies where 
progress has been slower than hoped.
For VISION 2020, increasing the 
available financial resources to 
implement national VISION 2020 plans 
and to bring good quality, equitable eye 
health services to the poorest commu-
nities is one very obvious area that 
requires our focus going forward. This 
will require extensive advocacy work, 
itself based on sound evidence, to 
influence and change the minds of policy 
makers around the world, most of whom 
presently see blindness as a low priority. 
More advocacy and more targeted 
research to prove our 
case (see article on 
page 43) are vital to 
our future progress. 
But even if we were 
able to get more 
money, would 
countries have the 
capacity to absorb it 
and actually deliver 
the much-needed eye 
health services? Sadly, the answer is no 
in many countries – because of the 
chronic shortage of 
eye health workers. Human resource 
development for eye health must receive 
even greater emphasis in the second 
decade of VISION 2020. Training is an 
important aspect of this but only one part 
of a complex jigsaw that includes wider 
policy issues such as staff retention and 
motivation, deployment to rural areas, the 
‘brain drain’ to high-income countries 
and/or private practice, and so on. 
Another important area to consider is 
the creation of consumer demand for 
eye health services. Why do so many 
people still turn to traditional treatments 
rather than seek out the eye units that 
VISION 2020 has so busily promoted? 
There are many reasons and this is not 
the place to investigate them in detail. 
But quality and 
access have to 
receive even greater 
attention than previ-
ously. For example, 
the quality of 
outcomes for 
cataract and trich-
iasis surgery is 
unacceptable in 
many countries and 
standards of surgery have to be improved. 
We also have to look for opportunities 
to promote VISION 2020 within the wider 
health development world. For example:
• The current emphasis of many of the big 
donor agencies is to support the 
strengthening of health systems, rather 
than fund individual vertical initiatives. 
At the very least, we shall need to 
consider how current VISION 2020 
approaches align with broader health 
system development. 
• The global shortage of health workers is 
a very serious problem that extends far 
beyond eye care – we cannot resolve 
our own need for more eye health 
personnel without taking account of 
initiatives such as the Global Health 
Workforce Alliance. 
• There are opportunities for us to engage 
with the reawakened global interest in 
primary health care.
All of the above will require us to make 
new partnerships that take us outside our 
traditional comfort zone within our own 
profession.
This may all seem rather daunting, but 
we must remember that there has been a 
huge amount of innovation and progress 
within VISION 2020. We have much to 
contribute to the world of health devel-
opment and others can learn as much 
from us as we can from them.
‘Scaling up’ is a commonly used term 
in development circles – but what does 
it mean? Recently, interesting work has 
been done to think through what 
scaling up really means in terms of 
international health. One approach is to 
consider the barriers that are currently 
preventing health approaches from 
being taken to scale. Take a look at 
www.expandnet.net for more
information on this interesting topic.
Scaling up
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‘We have to look for 
opportunities to 
promote VISION 2020 
within the wider health 
development world’
Checking a patient for cataract. BurunDi
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